AstraZeneca recently announced positive top-line data from two international, multi-center clinical trials in adult patients with chronic obstructive pulmonary disease (COPD) and in pediatric patients with asthma. The results show that Symbicort inhalation aerosol was well tolerated and achieved primary endpoints in both studies. Symbicort is a combination of budesonide,…
New research led by Wisia Wedzicha, a professor of respiratory medicine at England’s National Heart and Lung Institute (NHLI), reports an improved combination therapy for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. The study’s findings were published in the New England Journal of Medicine, titled “…
Sunovion Pharmaceuticals announced that it has filed a New Drug Application with the U.S. Food and Drug Administration (FDA), requesting that SUN-101 and eFlow be approved as a long-term maintenance treatment of airflow obstruction in patients with moderate to severe chronic obstructive pulmonary disease (COPD). SUN-101 (glycopyrrolate) is a long-acting muscarinic antagonist…
GlaxoSmithKline (GSK) and VentureWise are working together to bring educational programs about chronic obstructive pulmonary disease (COPD) to healthcare professionals in Australia. VentureWise is an Australian company that provides health insights, data-informed health professional education programs, and works with health professionals and consumers to resolve treatment problems. The company…
New resources from the American Academy of Family Physicians (AAFP) are available to help effectively diagnose chronic obstructive pulmonary disease (COPD) and asthma, and help patients self-manage the chronic conditions. The AAFP booklet “COPD and Asthma: Differential Diagnosis” for physicians, highlights the importance of short- and long-term monitoring, maximizing lung function,…
The Belgium health authority has approved Bellerophon Therapeutics‘ plans to initiate a Phase 2 clinical trial for INOpulse, the company’s pulsatile nitric oxide (NO) delivery device, to treat pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD). The decision followed data from Bellerophon’s Phase 2a study and proof…
Pulmatrix recently reported topline results from a Phase 1 pilot study evaluating PUR0200, an iSPERSE dry powder formulation incorporating a marketed long-acting and once daily bronchodilator, as a therapy for chronic obstructive pulmonary disease (COPD). Under collaborative terms and with support from the pharmaceutical company Mylan, Pulmatrix headed the pharmacokinetic…
Treating older adults with chronic obstructive pulmonary disease (COPD) with opioids may not be the best idea. Researchers at St. Michael’s Hospital, in Toronto, Canada, have shown that new opioid users have up to five times higher risk of death than non-opioid users. The findings were published recently in the…
A team of researchers at the University of North Carolina Wilmington (UNCW) is testing an exercise table that may help patients with chronic obstructive pulmonary disease (COPD) breathe easier “The most exciting thing about this team is that they are coming from all disciplines,” Justine Reel, associate dean for research and innovation…
ProterixBio, which specializes in products that aid in the development of new treatments for pulmonary conditions, including chronic obstructive pulmonary disease (COPD), announced the appointment of Fernando Martinez, MD, to its Scientific and Medical Advisory Board. “ProterixBio is thrilled to have Dr. Martinez join” the board, Grace E. Colón, PhD, ProterixBio’s…
Get regular updates to your inbox.